139 related articles for article (PubMed ID: 22639938)
1. A long-term study of a patient with anti-p200 pemphigoid: correlation of autoantibody levels with disease activity and an example of epitope spreading.
Monshi B; Groth S; Richter L; Schmidt E; Zillikens D; Rappersberger K
Br J Dermatol; 2012 Nov; 167(5):1179-83. PubMed ID: 22639938
[TBL] [Abstract][Full Text] [Related]
2. Anti-p200 pemphigoid.
Goletz S; Hashimoto T; Zillikens D; Schmidt E
J Am Acad Dermatol; 2014 Jul; 71(1):185-91. PubMed ID: 24767733
[TBL] [Abstract][Full Text] [Related]
3. Subepidermal blistering disease with autoantibodies to both the p200 autoantigen and the alpha3 chain of laminin 5.
Shimanovich I; Petersen EE; Weyers W; Sitaru C; Zillikens D
J Am Acad Dermatol; 2005 May; 52(5 Suppl 1):S90-2. PubMed ID: 15858518
[TBL] [Abstract][Full Text] [Related]
4. From anti-p200 pemphigoid to anti-laminin gamma1 pemphigoid.
Dainichi T; Koga H; Tsuji T; Ishii N; Ohyama B; Ueda A; Natsuaki Y; Karashima T; Nakama T; Yasumoto S; Zillikens D; Hashimoto T
J Dermatol; 2010 Mar; 37(3):231-8. PubMed ID: 20507386
[TBL] [Abstract][Full Text] [Related]
5. Development of a simple enzyme-linked immunosorbent assay for the detection of autoantibodies in anti-p200 pemphigoid.
Groth S; Recke A; Vafia K; Ludwig RJ; Hashimoto T; Zillikens D; Schmidt E
Br J Dermatol; 2011 Jan; 164(1):76-82. PubMed ID: 20854435
[TBL] [Abstract][Full Text] [Related]
6. Laboratory Diagnosis and Clinical Profile of Anti-p200 Pemphigoid.
Meijer JM; Diercks GF; Schmidt E; Pas HH; Jonkman MF
JAMA Dermatol; 2016 Aug; 152(8):897-904. PubMed ID: 27167149
[TBL] [Abstract][Full Text] [Related]
7. IgA anti-p200 pemphigoid.
Wozniak K; Hashimoto T; Fukuda S; Ohyama B; Ishii N; Koga H; Dainichi T; Kowalewski C
Arch Dermatol; 2011 Nov; 147(11):1306-10. PubMed ID: 22106117
[TBL] [Abstract][Full Text] [Related]
8. A patient with both bullous pemphigoid and epidermolysis bullosa acquisita: an example of intermolecular epitope spreading.
Fairley JA; Woodley DT; Chen M; Giudice GJ; Lin MS
J Am Acad Dermatol; 2004 Jul; 51(1):118-22. PubMed ID: 15243536
[TBL] [Abstract][Full Text] [Related]
9. Ex vivo pathogenicity of anti-laminin γ1 autoantibodies.
Florea F; Bernards C; Caproni M; Kleindienst J; Hashimoto T; Koch M; Sitaru C
Am J Pathol; 2014 Feb; 184(2):494-506. PubMed ID: 24300951
[TBL] [Abstract][Full Text] [Related]
10. Pathogenicity of autoantibodies in anti-p200 pemphigoid.
Vafia K; Groth S; Beckmann T; Hirose M; Dworschak J; Recke A; Ludwig RJ; Hashimoto T; Zillikens D; Schmidt E
PLoS One; 2012; 7(7):e41769. PubMed ID: 22911854
[TBL] [Abstract][Full Text] [Related]
11. Bullous pemphigoid positive for anti-BP180 and anti-laminin 5 antibodies in a patient with graft-vs-host disease.
Izumi R; Fujimoto M; Yazawa N; Nakashima H; Asashima N; Watanabe R; Kuwano Y; Kurokawa M; Hashimoto T; Tamaki K
J Am Acad Dermatol; 2007 May; 56(5 Suppl):S94-7. PubMed ID: 17434049
[TBL] [Abstract][Full Text] [Related]
12. Anti-laminin gamma-1 pemphigoid.
Dainichi T; Kurono S; Ohyama B; Ishii N; Sanzen N; Hayashi M; Shimono C; Taniguchi Y; Koga H; Karashima T; Yasumoto S; Zillikens D; Sekiguchi K; Hashimoto T
Proc Natl Acad Sci U S A; 2009 Feb; 106(8):2800-5. PubMed ID: 19196964
[TBL] [Abstract][Full Text] [Related]
13. Relapse-associated autoantibodies to BP180 in a patient with anti-p200 pemphigoid.
Kasperkiewicz M; Hoppe U; Zillikens D; Schmidt E
Clin Exp Dermatol; 2010 Aug; 35(6):614-7. PubMed ID: 19874345
[TBL] [Abstract][Full Text] [Related]
14. [Anti-p200 pemphigoid: Remission under mycophenolate mofetil (Cellcept®)].
Raffin D; Delaplace M; Roussel A; Estève E
Ann Dermatol Venereol; 2013 Dec; 140(12):784-7. PubMed ID: 24315224
[TBL] [Abstract][Full Text] [Related]
15. [Anti-p200 pemphigoid: clinical, diagnostic and therapeutic aspects].
Drerup KA; Wehkamp U
Hautarzt; 2020 Feb; 71(2):130-133. PubMed ID: 31501972
[TBL] [Abstract][Full Text] [Related]
16. [Anti-p200 pemphigoid].
Holtsche MM; Goletz S; Zillikens D
Hautarzt; 2019 Apr; 70(4):271-276. PubMed ID: 30868255
[TBL] [Abstract][Full Text] [Related]
17. An attempt to develop mouse model for anti-laminin γ1 pemphigoid.
Koga H; Ishii N; Dainichi T; Tsuruta D; Hamada T; Ohata C; Karashima T; Furumura M; Hashimoto T
J Dermatol Sci; 2013 May; 70(2):108-15. PubMed ID: 23410740
[TBL] [Abstract][Full Text] [Related]
18. Clinical and immunological features and outcome of anti-p200 pemphigoid.
Commin MH; Schmidt E; Duvert-Lehembre S; Lasek A; Morice C; Estival JL; Debarbieux S; Rigal E; Pauwels C; De Quatrebarbes J; Roussel A; Goujon E; Stoebner PE; Jouen F; Joly P
Br J Dermatol; 2016 Oct; 175(4):776-81. PubMed ID: 27037896
[TBL] [Abstract][Full Text] [Related]
19. Circulating IgA and IgE autoantibodies in antilaminin-332 mucous membrane pemphigoid.
Natsuga K; Nishie W; Shinkuma S; Moriuchi R; Shibata M; Nishimura M; Hashimoto T; Shimizu H
Br J Dermatol; 2010 Mar; 162(3):513-7. PubMed ID: 19751242
[TBL] [Abstract][Full Text] [Related]
20. Anti-p200 pemphigoid: a novel autoimmune subepidermal blistering disease.
Dilling A; Rose C; Hashimoto T; Zillikens D; Shimanovich I
J Dermatol; 2007 Jan; 34(1):1-8. PubMed ID: 17204094
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
